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Introduction
Aging is characterized by a progressive decrease in
skeletal muscle mass, which leads to a loss of muscle
strength and function. In 1989 Irwin Rosenberg
proposed the term sarcopenia (from the Greek=σαρχο
muscle, πενια=deficiency, poverty) to define the gradual
decline in muscle mass related to age.1-4
Some years later, Evans and Campbell5 defined
sarcopenia as age-related loss in skeletal muscle mass
that results in decreased strength and aerobic capacity
and thus functional capacity. Baumgartner et al. using
data from the New Mexico Aging Process Study, were
the first to propose an operational definition of
sarcopenia based on measure of lean mass as assessed
by dual-energy X-ray absorptiometry (DXA). Based
on the measuring of appendicular skeletal muscle
mass calculated as the sum of lean mass in the arms
and legs divided by height squared, subjects with
relative muscle mass more than two standard
deviations (SD) below the sex-specific mean of a
reference population consisting of 122 young subjects
aged 18 to 40 years from the Rosetta Study were
defined as sarcopenic.6
Janssen and colleagues proposed an alternative
definition of sarcopenia based on the skeletal muscle
mass index (SMI) obtained by dividing the skeletal
muscle mass in kg to body weight compared to 100,
with the identification of two classes of sarcopenia
(class I and class II, for SMI values respectively
between –1 and –2 SD and < –2 DS than the average
of a reference group of young persons included in the
NHANES III).7
Together with the decrease in muscle mass and
muscle strength, qualitative changes of skeletal
muscle tissue occur with aging, being mainly
characterized by atrophy of muscle fiber type IIa, fast-
twitch8 with a progressive decline in the efficiency of
the muscle (i.e., muscle strength developed for single
functional unit of muscle mass).9 At the same time, the
muscle atrophy is accompanied by an increase of the
connective and adipose tissue within the muscle.10
The loss of muscle in the elderly is caused by
multiple factors, such as the reduced synthesis of
anabolic hormones, i.e. growth hormone, androgens,
estrogens, and insulin-like growth factor-I, and the
increase of some inflammatory cytokines especially
interleukin-1β, tumor necrosis factor-α, and
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interleukin-6, which play a catabolic action.11 In this
context, in a recent study Rossi et al. showed that
higher serum levels of anti-inflammatory markers, in
particular IL-4 and IL-13, may play a protective role
on fat free mass (FFM) and performance maintenance
in elderly subjects.
The decrease in physical activity with aging
process, the insufficient protein intake and co-
morbidities are other key factors in the development
of strength and muscle mass loss.
A rapid decline in muscle mass has been observed
in older people who remain bedridden due to an
illness. It has been shown that bedridden patients show
an increase of urinary nitrogenous bases excretion due
to an increased protein catabolism,12,13 and that healthy
elderly subjects lose an average of 1 kg of muscle
mass in 10 days of bed rest which results in 16%
reduction of the isokinetic strength of the knee
extensor muscles.14 This marked loss is three times
greater than that observed in healthy young adults
after 28 days of bed rest.15
Epidemiology of sarcopenia
The prevalence of sarcopenia varies between 7 to
50% based on the diagnostic criteria, cutoffs chosen,
and methods used to measure lean body mass and
muscle strength.16,17 A recent systematic review
including a final sample of eighteen prevalence papers
showed higher prevalence of sarcopenia in
institutionalized older adults (14-33%), compared to
community dwelling elderly (1-29%) or subjects
admitted to acute care hospitals (10%).18 A prevalence
increase was observed with age with no significant
differences between men and women.
In a recent cross-sectional observational study on
730 elderly people, a higher prevalence of sarcopenia
was demonstrated in subjects with chronic diseases
(heart failure, cognitive impairment, Parkinson’s
disease, renal failure, peripheral artery disease and hip
fracture) and people with low educational level.19
Health consequences of sarcopenia
Sarcopenia is a subject of increasing interest in the
scientific community for its multiple clinical and
epidemiological implications. In fact, sarcopenia,
which is characterized by progressive loss of skeletal
muscle mass and strength, results in physical disability,
reduced quality of life, and increased risk of fractures,
hospitalization and mortality.20-24 A recent multicenter
observational study involving 770 hospitalized patients
showed a significantly higher in-hospital and 1-year
mortality in participants with sarcopenia diagnosed
according to EWGSOP criteria.25
Definition and diagnostic criteria
The first definition of sarcopenia was based only
on skeletal muscle mass measurement by DXA or
bioimpedantiometry (BIA).6,7,26
This definition of sarcopenia used in several
epidemiological studies has important limitations. In
fact, several studies showed that age-related decline in
muscle strength is quicker and poorly correlated with
the decline in muscle mass. Although muscle mass is
an important determinant of muscle strength,27-29 age-
related loss of muscle mass only partially explains the
loss of muscle strength. In a metanalysis Manini and
Clark showed that low lean mass is generally a poor
predictor of impaired physical performance, physical
disability and functional limitation, outcomes more
related to muscle weakness.30
Since 2010, several groups of experts and in
particular the European Working Group on Sarcopenia
in Older People (EWGSOP) and the International
Working Group on Sarcopenia (IWG) have convened
with the goal of establishing consensus diagnostic
criteria for sarcopenia taking into account also its
functional consequences.31-33 All the consensus groups
agree in stating that a sarcopenia diagnosis should
include both low muscle mass and poor muscle
function as assessed by either low muscle strength or
impaired physical performance.
The EWGSOP established three criteria for a
diagnosis of sarcopenia: i) criterion 1: decreased muscle
mass; ii) criterion 2: reduction of muscle strength; iii)
criterion 3: decreased physical performance.
The documented presence of the criterion 1
associated with criterion 2 or criterion 3, allows a
diagnosis of sarcopenia (Table 1).32
The EWGSOP suggests three different stages of
sarcopenia which attest the severity of the condition:
presarcopenia, sarcopenia, and severe sarcopenia.
The presarcopenia is characterized by the loss of
muscle mass not associated with strength or physical
performance loss. The sarcopenia is defined by the
reduction in muscle mass associated with strength or
physical performance loss. The severe sarcopenia is
characterized by the presence of the three diagnostic
criteria.
Identifying the different stages of sarcopenia can
be useful for establishing the treatment and defining
appropriate recovery objectives.
More recently, in order to create a new definition
of the criteria for sarcopenia validated by larger
studies, it was approved The FNIH Sarcopenia Project
promoted by the Foundation for the National Institutes
of Health (FNIH), a public/private partnership made
up of representatives of the National Institute of
Aging, the National Institute of Arthritis and
Musculoskeletal and Skin Diseases, the Center for
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Drug Evaluation and Research/Food and Drug
Administration, several leading academic institutions
and six pharmaceutical companies.
The FNIH Sarcopenia Project analyzed results
from nine large population studies with longitudinal
measures of muscle mass and function (Age,
Gene/Environment Susceptibility-Reykjavik Study,
Boston Puerto Rican Health Study, 6 clinical trials of
the University of Connecticut; the Framingham Heart
Study, the Health, Aging, and Body Composition
Study, the Aging InChianti study; the Osteoporotic
Fractures in Men Study, Rancho Bernardo Study,
Study of Osteoporotic Fractures), for a total of 26,625
men and women aged 65 years and older.
The Project recently published a series of five
papers33-37 describing rationale, methods, and
recommendations resulting from a year-long effort
supported by the FNIH Biomarkers Consortium.
Specifically the Sarcopenia Project aimed to
determine a level of muscle weakness associated with
mobility disability and a degree of muscle mass that
identifies muscle weakness and to evaluate whether
the criteria for muscle weakness and low lean mass
are associated with incident mobility impairment
defined as gait speed less than 0.8 m/s. Sex-specific
cut-points for handgrip strength that discriminate
individuals with mobility impairment34 and cut-points
for appendicular lean mass measured by DXA, that
were associated with weakness defined by the
previously calculated cut-points,35 were obtained.
Absolute appendicular lean mass emerged as the
single best discriminator of weakness (low grip
strength). Taking into account the obesity influence on
the relationship between lean mass and muscle
strength, alternative cut-points for appendicular lean
mass standardized to body mass index (BMI) were
proposed as a discriminator of weakness.
Low appendicular lean mass standardized to BMI
was associated with a more modest increased risk of
mobility impairment compared to low grip strength,
whereas low absolute appendicular lean mass was not
associated with mobility impairment.32
Among those classified as weak by the low grip
strength criteria, the risk of mobility limitation did not
differ between those with and without low lean mass,
indicating that weakness is the primary determinant of
future mobility problems. Nevertheless, the
investigators noted that among those with weakness
there was likely a subgroup for whom low lean mass
was the underlying cause of their weakness, and these
individuals could be targeted for treatment with
therapies that increase muscle mass. Thus, the
Sarcopenia Project recommended a set of sex-specific,
empirically-derived cut-points for low absolute grip
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Table 1. Different definitions of sarcopenia.
                     European Working Group       International working group   Special interest Group:             Sarcopenia with limited
                     on Sarcopenia in Old People    on sarcopenia (IWG)                 Cachexia-anorexia in                mobility: an international
                     (EWGSOP)                                (Fielding RA)                             chronic wasting disease            consensus
                     (Cruz-Jentoft AJ)                                                                           (Muscaritoli M)                         (Morley JE)
Definition     Syndrome characterized by         The loss of muscle mass and       The term sarcopenia originally   Reduced muscle mass, with
                     a progressive generalized            strength associated with aging    referred solely to the loss of        limited mobility
                     muscle strength and mass loss                                                         muscle mass with age, and
                     with increate risk of                                                                         as such, is an almost universal
                     unfavorable events such as                                                              phenomenon
                     physical disability, reduced                                                             Current sarcopenia definitions
                     quality of life and increased                                                            incorporate not only muscle
                     mortality                                                                                         mass but also elements such
                                                                                                                              as strength and function
Criteria         1. Low muscle mass +                 1. Low muscle mass                    1. Recommended cutoff for         1. ALM corrected for height
                     2. Low muscle strength               (i.e. a percentage of muscle         weakness: grip strength               squared of more than 2 
                     or                                                 mass 2 standard deviations          (GSMAX) <26 kg for males       standard deviations below
                     3. Low physical performance      below the mean measured in       and <16 kg for females               that of healthy persons 
                                                                         young adults of the same            Alternate: grip strength               between 20 and 30 years of
                                                                         sex and ethnic background)        adjusted for BMI                         age of the same ethnic group
                                                                         2. Low walking speed                 (GSMAXBMI) <1.0 for              2. Walking speed <1.0 m/sec
                                                                         (<0.8 m/s over 4 meters              males <0.56 for females              o <400 m at the 6 min
                                                                         gait speed test)                             2. Recommended cutoff for         walking test
                                                                                                                              low muscle mass:
                                                                                                                              ALM adjusted for BMI
                                                                                                                              (ALM/BMI) <0.789 for
                                                                                                                              males <0.512 for females
                                                                                                                              Alternate: ALM <19.75 kg
                                                                                                                              for males <15.02 kg
                                                                                                                              for females
ALM, appendicular lean mass; BMI, body mass index.
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strength and low appendicular lean mass standardized
to BMI as potential criteria for clinically relevant
weakness and low lean mass, respectively, in older
men and women (Table 1).
Qualitative changes occurring in sarcopenic
skeletal muscle
Within aging, the total number of motor units
(motor neuron and muscle fibers associated) decreases
with a prevalent loss of fast-twitch muscle-skeletal
fibers (type IIa); the remaining fibers, both type I and
type II fibers, undergo atrophy, histologically
detectable with a reduction of their section area.38
The age-related decrease in the number of neurons,
at cortical, medullary and peripheral levels, is an
important causal factor of motor units’ depletion. As an
adaptation mechanism, new neuro-muscular junctions
are generated between the residual nerve endings and
the muscle fibers that have undergone denervation (type
I and type II), generating new motor units in which a
single motor neuron innervates both slow and rapid
twitch muscle fibers. The result of this process is the
loss of muscle efficiency (that is, of the muscle strength
developed for each functional unit of muscle mass).
This set of modifications determines an important
deterioration in physical performance with a 30-35%
decrease in muscle strength.39
Further, another morphological aspect consists in
lipid infiltration both within adipocytes located
between the muscle fibers and at the cytoplasmic level
of the muscle cells themselves (intramyocellular fat).40
At ultrastructural level, mitochondrial dysfunction
causes excessive production of reactive oxygen
species causing accumulation of mitochondrial DNA
damage; this can trigger apoptosis with subsequent
programmed death of the entire fiber by the release of
cytochrome c into the cytosol, or by the production of
pro-apoptotic proteins.41,42
Also, the oxidative stress that occurs into
sarcoplasmic reticulum can lead to apoptosis by release
of calcium in the cytoplasm with consequent activation
of the effector caspases. Regarding the sarcomeric
structures, in addition to a significant decrease in the
total amount of myosin per single fiber, there is
accumulation of post-transcriptional modifications,
such as the glycation of proteins, with impairment of
the correct interrelation between actin and myosin,
reduction of the efficacy of the muscle contraction.43
Methods for muscle mass evaluation
Several methods have been proposed for muscle
mass evaluation. Although BIA and anthropometry
may be easily applicable in the clinical field, they are
often considered inaccurate methods for muscle mass
evaluation.44 In contrast, DXA that estimates
appendicular and total body lean mass, and computed
tomography (CT) which measures muscle cross
sectional area are considered more reliable and
reproducible methods.
Among regional measures of muscle mass, the mid
arm circumference measured at the midpoint of the
upper arm and recorded to the nearest 0.1 cm was the
most frequently used. However, this method was
limited by the assumption for its use, that the midarm
is circular, the triceps skinfold thickness is twice the
average fat diameter at the middle of the upper arm.44
Sex-specific equations have been previously proposed
containing corrections for bone contributions, resulting
in average intra-rater error of 7% to 8% in the
calculated midarm muscle area. By using this formula
in obese subjects an average 50% error was observed.45
More recently Lee et al. proposed a predictive
equation using upper-arm girth adjusted for skinfold,
thigh circumference corrected by anterior thigh
skinfold and height, and calf circumference corrected
by skinfold thickness.46
SMM=S (0.00744 CAG2+0.00088 CTG2+0.00441
CCG2) +2.4 Sex – 0.048 Age                                 (1)
where CAG is corrected upper-arm girth adjusted for
skinfold thickness, CTG is thigh circumference
corrected for anterior thigh skinfold thickness, CCG
is calf circumference corrected for skinfold thickness,
S is stature in m, age is in years, sex is 1 for male and
0 for female, and race is –2 for Asians, 1.1 for African
American, 0 for white or Hispanic.
Bioelectrical impedance analysis is widely used for
assessing muscle mass. This method relies on the
conduction of a low electrical current and allows
measuring two parameters: resistance (R) and reactance
(Xc). Reference body composition data to validate the
BIA-based measurements were derived from
anthropometric assessment and CT measurements of
muscle and fat area, and several equations have been
proposed for muscle mass estimation.44
Roubenoff and colleagues developed the following
BIA equations to quantify FFM:47
9.1536+0.4273 height2/R+0.1926 weight
+0.0667 Xc for men                                                (2)
7.7435+0.4542 height2/R+0.1190 weight
+0.0455 Xc for women                                           (3)
where height is in cm, age in years and R in ohm; sex:
male=1, female=0.
Alternative regression equations, the most used in
studies conducted in elderly populations, were
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proposed and validated in a multiethnic sample of 388
men and women aged 18 to 86 years by Janssen to
estimate skeletal muscle mass (SMM):48
SMM=0.401 (Ht2/R)+3.825 Sex – 0.071 Age+
5.102                                                                       (4)
where R is resistance (ohm) determined at 50 kHz, Ht
is height (cm), sex is male =1 and female =0, and age
is in years.
The inhomogeneous composition of body
compartments, cross-sectional areas variability, FFM
hydration fraction, presence of edema and differences
in conductor lengths from limbs and trunk limits the
use of BIA equations from one population to another
and the same equation cannot be used indifferently in
populations with different age, BMI or hydration
status.49 However bioelectrical impedance does not
require a prolonged training and is a widely available
and inexpensive instrument for routinely use.
DXA is a radiologic technique that offers the
opportunity to direct measure muscle, fat and bone
mass. This technique, originally developed for bone
mineral content assessment, has been refined for
assessment of soft tissue composition. DXA exposes
the patient to a much less amount of X-ray compared
with CT.50
Validation studies for DXA indicate good
agreement with CT and multicompartment models,
considered as reference methods.
Second generation DXA are equipped with fan-
beam technology that allows much less time to
complete whole-body composition and bone density
scan with improved precision.51 Fan beam machine
has been used frequently in clinical trials and also in
the National Health and Nutrition Survey IV.
Comparison studies, assessing body composition with
DXA pencil-beam and fan-beam have found that the
latter measurement overestimates lean mass with, on
the counterpart, an underestimation of fat mass with
differences between various hardware and software
between 1% and 5% for different tissues.52,53
DXA has the advantage, as compared with BIA,
that allows, not only total body, but also regional body
composition assessment and in particular appendicular
lean mass measurement.
Potential interference of fluid accumulation in the
body should be considered even when using DXA, but
to a lesser extent as compared with BIA.
Hydration status alterations, for example
consumption of 1 to 2.4 L of water 1 hour before DXA
scan could determine an increase of FFM, because of
alteration of extracellular fluid volume, whilst the
ingestion of small amount of water did not affect body
composition measurement.
DXA is considered a reasonable alternative for
muscle mass assessment compared to much more
sophisticate, time-consuming and expensive
techniques such as magnetic resonance imaging
(MRI) and CT. DXA likely represents the most
accessible technique for high quality and precise body
composition assessment. The radiation exposure
associated with DXA is low and highly acceptable
(i.e., about 1 mrem; similar to that of a 3-day
background). Nevertheless, even this low dose
radiation needs to be considered as a limiting factor
for routine assessment of body composition.
The main limitations of DXA reside in the
instrument cost44 and by the dimensions of the table
of the densitometer, which is limited in size and
weight and therefore may not be suitable for the
evaluation of subjects with high-grade obesity.
CT scan is based on X-rays that pass through the
different body tissues and are attenuated in relation to
the physical density of the tissues examined. The CT
method offers high quality images with clear
distinction between fat and other soft tissues.
CT and MRI are considered gold standards for
clinical research, although they are expensive and
difficult to adopt on a large scale.44
This allows a clinician to visually and
mathematically distinguish the different tissues with
dedicated software and in particular at the muscle
level to separate intermuscular adipose tissue from
mean skeletal muscle based on the differences in
attenuation characteristics.54
CT has high precision with <1% of error and is
considered the best method to measure body
composition changes and the effect of life style
interventions in humans.
The most important limitation for the routine use
of CT exposes individuals to ionizing radiation (i.e.,
about 15 mrem, much higher than DXA) and provide
a marker of muscle fat content but not a quantitative
determination of fat content.44 Advantages are the
reliability and the relative simplicity.
Several studies support the validity of MRI
estimates to quantify skeletal muscle by comparison
with the dissection in human cadavers. Mitsioupoulos
et al.55 compared the cross-sectional area measurements
of skeletal muscle and subcutaneous adipose tissue
determined from the entire arm and leg regions of
cadavers with corresponding MRI-measured cross-
sectional areas and reported the correlation coefficient
between the two approached units.
Limitations for the use of MRI in body
composition studies are attributed to limited access
of instrumentation, the higher technical complexity
and costs, time required for scan acquisition (about
45 min), and the inability to evaluate subjects with
older models of implanted metal devices (e.g., joints,
pace-makers, metallic particles in the eye, etc.). On
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the other hand, MRI shows a high agreement with
the CT and provides similar measures. It does not
involve radiation exposure and, furthermore, it also
has the additional capacity of multiple slice
acquisition (thus, rendering 3D volumetric estimates
for muscle mass).
Methods for muscle strength evaluation
Different assessments have been proposed to
measure muscle strength in the geriatric population.
To date, the most widely used method in clinical
practice appears to be the handgrip strength
dynamometry because of its simplicity, time-
efficiency, affordability, and reliability. This method
has been shown to reflect the overall strength status
of an old subject and to be a good predictor of
morbidity, hospitalization and mortality.56
Standardized conditions for the test57 include seating
the subject in a standard chair with their forearms
resting flat on the armchairs; six measures should be
taken, three with each arm; the highest reading of the
6 measurements is reported as the final result.
According to guideline for European working group
on sarcopenia in older people (EWGSOP, the
Sarcopenia Working Group), low muscle strength,
using cut-off point for handgrip strength at two
standard deviations below the mean reference value,
is defined as <30 kg in men and <20 kg in women.18
Since lower extremity strength and in particular
muscle extensor appear to be crucial in a variety of
functional tasks, knee extension strength measured by
isokinetic and/or isometric dynamometry has also
been proposed as tool for quantification of muscle
strength in elderly. However, although the
measurement is feasible in frail older people,58,59 its
practical applicability seems to be limited because it
is more complex and time-consuming, and so far,
there are limited data in older population.
Sarcopenia is not confined to only upper or lower
limb muscles but rather involves a more generalized
loss of skeletal muscle mass and strength, including a
decline in mass and strength of the respiratory chest
muscles.60,61 The EWGSOP used peak expiratory flow
(PEF) value to measure respiratory muscle strength in
people without lung disorders.18 However, studies on
respiratory function and sarcopenia are limited and
PEF values cannot currently be recommended for use
as a single parameter of muscle strength.
Methods for physical performance evaluation
Gait speed, sit-to-stand time and standing balance
are the most widely used tools for the assessment of
functional performance. They can be evaluated as
single items, but, in clinical practice, they are more
often measured within the context of the short physical
performance battery (SPPB).62 The SPPB is really the
most commonly employed method of assessing the
ability to perform the activities of daily living in
mobility-limited older adults;63 it focuses primarily on
lower extremity function and includes a 4 meter walk
to measure gait speed, one chair stand (followed by 5-
time chair stands, if the first is successfully
completed), and balance stands with the feel held in
different positions for 10 sec each. The test is easily
administered in a variety of contexts or settings, and
a score between 0 and 4 is assigned to each component
(with a maximum of 12 points). Participants
presenting a score ≤8 points have been described as
having a poor physical performance.18
Although the usual gait speed test measured as the
pace on a 4- or 6-m course is the most popular
physical function and performance test in clinical
practice, and sarcopenia research and is often referred
to as the new vital sign because it is a sensitive
predictor of physical disability, fall risk, chronic
illness and premature death and has been strongly
associated with independent functioning in older
adults,64,65 other independent tests used to assess
physical performance include the 6-min walk distance
(6MWT) or 400 m walk test, the stair climb power
test, the timed up and go (TUG) test.18
In the TUG test subjects are asked to stand up from
a standard chair (seat height between 44 and 47 cm),
walk a distance of 3 m (marked on the floor) at a
comfortable pace, turn, walk back and sit down. The
TUG is an easy-to-apply, fast and inexpensive test; it
serves as an assessment of dynamic balance, and it has
been shown to be a good predictor of sarcopenia in
elderly hospitalized patients66 as well as in home-
dwelling elderly persons.67
Longer distance walking tests are also used as valid
alternative tools to evaluate the exercise capacity at
levels corresponding to efforts commonly performed
by elderly during daily activities. Some versions of
these tests measure either distance traveled in a set
amount of time, as for the 6MWT that measures the
distance an individual is able to walk in 6 minutes on a
hard, flat, indoor surface, or the time to walk a set
distance, such as the usual-pace 400 m walk.68 These
tests have been shown to be good indicators of
functional performance in older adults,68,69 and have
been used as an outcome in clinical trials, however they
only include walking ability.
The stair climb power test assesses the ability to
ascend and descend a flight of stairs, as well as lower
extremity strength, power, and balance.69 It may be of
some use in research settings.18
Finally, jumping mechanography, a procedure that
uses maximal countermovement jumps to assess
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muscular power, has been proposed as new tool to
assess muscular function in older adults.70 The test is
a strength measurement of muscle that incorporates
the functional components assessed in traditional chair
rise and gait speed testing. It has been shown that jump
test variables are positively correlated with lean tissue
and lower body muscle strength70 and that in older
adults has excellent retest reliability that was
comparable to grip strength and possibly better than
SPPB and gait speed, is stable over time, and can be
performed safely.70,71 However, more studies in older
populations and comparison of this approach with
traditional assessment tools in longitudinal
interventional studies are needed.
Questionnaires for sarcopenia screening
As previously reported, the EWGSOP, as well as
the International Working Group on Sarcopenia
(IWGS), established three criteria necessary for the
diagnosis of sarcopenia, namely decreased muscle
mass, reduction of muscle strength and/or decreased
physical performance. Besides the EWGSOP consensus
statement on sarcopenia, a number of other definitions
have been published.72,73 Therefore, the diagnostic
criteria include muscle mass, gait speed and/or handgrip
measurements that must be performed by trained
operators and preferably in a laboratory assessment.
Since these measurements are not always available
and easily performed in general practitioner, acute-
care and long-term care settings, there is need for an
easy-to-use and widely available pre-screening tool to
identify the risk of sarcopenia. Moreover, it has been
shown that the gait speed test, the first step for
EWGSOP diagnosis criteria, cannot be performed in
nearly half of the elderly population within previously
described settings.74,75
Moreover, the prevalence of sarcopenia among the
different study populations varies depending on
whether IWGS or EWGSOP criteria were used,76 the
variations widely explained by the use of different
muscle indices. As a consequence, also in order to
reduce the costs related to diagnosis, recent emphasis
has been placed on the diagnosis of clinically
important sarcopenia, developing tools able to identify
clinical risk parameters of sarcopenia.
Malmstrom and Morley developed a 5-item
questionnaire, the SARC-F, based on principal
features and health consequences of sarcopenia, as
described in literature.77-79
The SARC-F scale includes questions that
investigate strength, assistance walking, rise from a
chair, climb stairs and falls. Strength was measured by
asking subjects how much difficulty they had lifting
or carrying 10 lbs (0=no difficulty, 1=some, and 2=a
lot or unable to do). Assistance walking was
investigated by asking participants how much
difficulty they had walking across a room and whether
they used aids or needed help to do this (0=no
difficulty, 1=some, and 2=a lot of difficulty, use aids,
or unable to do without help). Rise from a chair was
measured by asking respondents how much difficulty
they had transferring from a chair or bed and whether
they used aids or needed help to do this (0=no
difficulty, 1=some, and 2=a lot of difficulty, use aids,
or unable to do without help). Climb stairs was
measured by asking respondents how much difficulty
they had climbing a flight of 10 steps (0=no difficulty,
1=some, and 2=a lot or unable to do). Falls were
scored a 2 for respondents who reported falling four
or more times in the past year, 1 for respondents who
reported falling 1-3 times in the past year, and 0 for
those reporting no falls in the past year. The score
range obtained with the SARC-F questionnaire ranges
from 0 to 10 (0-2 points for each item, 0=best score,
10=worst), dichotomized to represent symptomatic
subjects (score ≥4) compared to the healthy ones
(score 0-3).
Malmstrom et al. investigated the utility of SARC-
F in the African American Health (AAH) study,
Baltimore Longitudinal Study of Aging (BLSA) and
National Health and Nutrition Examination Survey
(NHANES).
The AAH study includes community-dwelling,
late middle-aged African Americans aged between 49-
65 years old at initiation in 2000-2001 and had high
level of disability.80,81 The BLSA is an ongoing survey
started in 1958 on normal human aging; subjects
included were healthy adults at the time of enrolment.
The NHANES is a nationally representative study of
approximately 5000 community-dwelling individuals.
In the AAH cohort, subjects with SARC-F score
≥4 showed more deficits in the instrumental activities
of daily living (IADL) than those who scored 3 or less,
longer standing-time from the chair, lower grip
strength, lower SPPB scores with poorer physical
performance, higher probability of hospitalization and
of having a gait speed <0.8 m/s.82 SARC-F score ≥4
in BLSA was associated with higher IADL deficits,
worse grip strength (at both right and left hands) and
mortality in follow-up (39.4% for SARC-F ≥4 vs 8.0%
in SARC-F <4). NHANES participants with SARC-F
scores ≥4 had lower walking speeds (slower time to
walk 20 ft), lower strength (knee extension) and were
more likely to have been hospitalized recently in
cross-sectional analysis.
Cao et al. showed that SARC-F was associated
with poor physical performance, grip strength and
hospitalization in the previous 2 years.83 In this study,
two hundred and thirty Chinese people over 65 years
of age were assessed by the SARC-F scale, physical
self-maintenance scale (PSMS),84 IADL, and the
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shortened version of the falls efficacy scale-
international (the short FES-I).85 Physical performance
and strength were measured respectively with the
SPPB and handgrip test; hospitalization was also
investigated. Poor physical performance and grip
strength were independently associated with a SARC-
F score ≥4. The short FES-I was correlated to
SARC-F, poor PSMS and IADL scores were
associated with SARC-F ≥4 and SARC-F ≥4 was
associated with hospitalization in the past 2 years.
Woo et al. conducted a validation study of SARC-
F on a cohort of 4000 Chinese community residents
aged 65 and over.86 SARC-F has been validated and
compared with the three definitions of sarcopenia for
the European consensus groups (EWGSOP), Asian
(AWGS) and the international group (IWGS); the
ability of all four diagnostic tools to predict physical
limitation at four years of follow-up, walking speed
and ability to stand up from a chair was compared.
Sarcopenic subjects according to SARC-F, EWGSOP,
IWGS and AWGS all showed increased risk of
physical limitations and poor physical performance at
follow-up, both men and women. The SARC-F
questionnaire showed a high specificity (94-99%) and
high negative predictive value, but low sensitivity
(4.2% men and 9.9% women) for sarcopenia by using
the EWGSOP criteria.
More recently Rossi et al. developed the Mini
Sarcopenia Risk Assessment (MSRA) questionnaire
as a prescreening tool for assessing the risk of
sarcopenia.87
The questionnaire is composed of seven items and
investigates anamnestic and nutritional characteristics
related to the risk of occurrence of sarcopenia; four
questions about general assessment (age ≥70 or <70
years, physical activity level as walking more or less
than 1000 meters, number of hospitalizations in the
previous year and weight loss), and three about
nutritional status (consumption of proteins and dairy
products, number of meals per day). These questions
reflect risk factors of muscle mass and strength loss
as shown in literature.
MRSA was used in a post-hoc observational study
of a community-aged population of 274 subjects, 177
women and 97 men, aged 66-78 years. According to
the EWGSOP diagnostic criteria, the subjects of the
study were classified as sarcopenic and not sarcopenic.
The results showed that 33.5% of the study
population was classified as sarcopenic. Using the form
of MRSA extended to 7-item, subjects with a score
equal to or less than 30 had a 4-fold higher risk of being
sarcopenic than subjects with a score greater than 30,
taken as a cut-off value [odds ratio (OR): 4.20; 95%
confidence interval (CI): 2.26-8.06]; the area under the
ROC curve was 0.786 (95% CI: 0.725-0.847).
In a logistic regression, considering the probability
of being sarcopenic as the dependent variable and the
variables corresponding to the 7 items of the
questionnaire as independent, two items (number of
meals and consumption of milk and dairy products)
showed not significant diagnostic power. A cut-off
score for the 5-item questionnaire was then obtained,
where the area under the ROC curve was 0.789 (95%
CI: 0.728 to 0.851).
Taking into account the cost of false positives and
false negatives and the prevalence of sarcopenia, the
optimal threshold of the original MSRA score based
on 7 items is therefore 30, with a sensitivity of 0.804
and a specificity of 0.505, while the threshold optimal
of the MSRA score based on 5 items is 45, with a
sensitivity of 0.804 and a specificity of 0.604.
In this preliminary study, the MSRA questionnaire
was predictive of sarcopenia and may be suggested as
a pre-screening tool to detect this condition. In
particular, the use of the short form of the MSRA
questionnaire improves the ability to identify
sarcopenic subjects, for sensitivity and specificity
values (Tables 277 and 387).
Conclusions and perspectives
The research in the field of sarcopenia has
progressed significantly over the past decade, but yet it
continues to lag behind the clinical assessment,
treatment, and outcomes that have been well-
established in the field of osteoporosis. With the
EWGSOP and IWG consensus and the ongoing FNIH
activities in the Biomarkers Consortium, further
refinements of sarcopenia criteria are expected.
The validation of the MSRA and SARC-F
questionnaires should be part of further prospective or
retrospective studies in wider populations. The MSRA
and SARC-F questionnaires are designed to provide an
inexpensive and easy-to-use tool capable of capturing
the key features of sarcopenia and rules out subjects
unlikely to be sarcopenic. They have the advantage that
can be compiled also by the patient or by the caregiver
and are applicable in postal screening, phone calls or
general practitioners settings as well, thus allowing the
screening for sarcopenia in outpatients.
While further studies are needed to provide a full
evidence-based guidance, the management and
assessment of sarcopenia is very important in the
mainstream of clinical care to ensure a reduction in
age-related falls, fractures, and disability and to
guarantee a better quality of life with aging.
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